Alentis develops breakthrough treatments for fibrotic diseases.
The pipeline includes specific antibodies against Claudin-1, a novel target in fibrosis and cancer.
Unlike most therapies Alentis’ approach aims at a direct reversal of disease progression. The lead asset will enter clinic end 2021.


Hochbergerstrasse 60C, 4057 Basel, Switzerland

Facts & figures
  • Type of organization
    Private company
  • Number of employees in Switzerland
Key business